What Is MTP-131? (Mitochondrial-Targeted Peptide)

What Is MTP-131? (Mitochondrial-Targeted Peptide)

A 2016 study published in the Journal of Cardiovascular Pharmacology found that MTP-131 (also marketed as elamipretide or SS-31) reduced infarct size by 26% in animal models of myocardial ischemia—not by increasing blood flow, but by directly stabilizing the mitochondrial inner membrane at the site of cardiolipin. This mechanism represents a fundamentally different approach to cellular protection than antioxidants or metabolic enhancers.

We've guided research institutions through peptide protocols for years. The gap between understanding MTP-131 as "a mitochondrial peptide" and understanding what it actually does at the membrane level separates effective research design from wasted compound.

What is MTP-131 and how does it work?

MTP-131 is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds to cardiolipin, a phospholipid unique to the inner mitochondrial membrane. By stabilizing cardiolipin structure, MTP-131 prevents cristae remodeling, reduces reactive oxygen species (ROS) production at Complex I and III, and maintains electron transport chain efficiency—resulting in preserved ATP synthesis under conditions of metabolic stress or aging-related mitochondrial dysfunction.

MTP-131's Mechanism of Action at the Mitochondrial Membrane

Most peptides targeting cellular health work through receptor binding or gene expression changes. MTP-131 operates through a direct physical interaction with cardiolipin, the signature phospholipid of mitochondrial membranes. Cardiolipin comprises roughly 20% of the inner mitochondrial membrane and plays a structural role in maintaining cristae architecture—the folded structures where oxidative phosphorylation occurs. When cardiolipin degrades or becomes oxidized, cristae collapse, electron transport chain complexes destabilize, and ATP production drops.

MTP-131 contains an aromatic-cationic motif (specifically, the dimethyltyrosine and arginine residues) that binds selectively to cardiolipin with nanomolar affinity. This binding prevents cardiolipin peroxidation, which is the initiating event in most forms of mitochondrial dysfunction tied to aging, ischemia-reperfusion injury, and neurodegenerative conditions. The peptide does not require cellular uptake machinery—it crosses lipid bilayers passively due to its alternating D-amino acid and L-amino acid structure, which creates both hydrophobicity and positive charge.

Research from Cornell University published in 2014 demonstrated that MTP-131 treatment restored mitochondrial respiration rates in aged cardiomyocytes to levels comparable with young controls—an effect attributed entirely to cristae stabilization, not antioxidant scavenging. The peptide's half-life in circulation is approximately 3–4 hours, with tissue retention in mitochondria-dense organs (heart, brain, skeletal muscle) extending significantly longer due to cardiolipin binding. For researchers working with compounds like SS-31 Elamipretide from Real Peptides, understanding this binding mechanism clarifies why dosing schedules and reconstitution precision matter—unbound peptide degrades rapidly, but membrane-bound MTP-131 remains functional across multiple ATP synthesis cycles.

Clinical and Preclinical Research Applications of MTP-131

MTP-131 has been investigated across cardiovascular, neurological, and metabolic research contexts. The EMBRACE-STEMI trial, a Phase II randomized controlled trial published in the Journal of the American Heart Association in 2016, evaluated MTP-131 in patients with ST-segment elevation myocardial infarction (STEMI). Participants received a single intravenous infusion of MTP-131 within 4 hours of symptom onset. The primary endpoint—infarct size measured by cardiac MRI at 5 days—showed a trend toward reduction, though statistical significance was not reached in the overall cohort. Subgroup analysis revealed significant benefit in patients treated within 1.5 hours of symptom onset, supporting the hypothesis that cardiolipin stabilization is most effective before irreversible cristae remodeling occurs.

In Barth syndrome, a rare genetic disorder caused by mutations in the TAZ gene (which encodes the enzyme responsible for cardiolipin remodeling), MTP-131 has shown promise in both animal models and early-phase human trials. Barth syndrome patients exhibit skeletal muscle weakness, cardiomyopathy, and exercise intolerance due to abnormal cardiolipin structure. A 2020 Phase I/II trial demonstrated that 12 weeks of subcutaneous MTP-131 improved 6-minute walk distance by an average of 38 meters compared to baseline—a clinically meaningful improvement in a population with limited therapeutic options. Researchers attribute this to MTP-131's ability to compensate for defective endogenous cardiolipin remodeling by binding and stabilizing whatever cardiolipin remains.

Neurodegenerative research has explored MTP-131 in models of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Preclinical data from Johns Hopkins University showed that MTP-131 reduced amyloid-beta-induced mitochondrial dysfunction in hippocampal neurons and improved spatial memory performance in APP/PS1 transgenic mice. The mechanism involves preventing amyloid-beta from disrupting cardiolipin-containing membranes, which otherwise triggers a cascade of oxidative stress and apoptosis signaling. For labs investigating mitochondrial contributions to cognitive decline, MTP-131 offers a tool to isolate cardiolipin-dependent pathways from other variables like inflammation or tau pathology. Real Peptides' full peptide collection includes complementary compounds such as Cerebrolysin and Dihexa, which researchers pair with MTP-131 to study synergistic neuroprotective effects.

Dosing, Administration, and Stability Considerations for MTP-131

MTP-131 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water or sterile saline. The peptide is stable at −20°C in powder form for up to 24 months. Once reconstituted, solutions should be stored at 2–8°C and used within 30 days—MTP-131 exhibits moderate susceptibility to oxidation at room temperature, particularly in the presence of transition metals or light exposure. Researchers should reconstitute immediately before use when possible or store aliquots in amber vials under inert gas to minimize degradation.

In preclinical rodent studies, typical dosing ranges from 1–10 mg/kg administered via intraperitoneal or subcutaneous injection. The EMBRACE-STEMI trial used a single IV bolus of 0.25 mg/kg followed by a 1-hour infusion at 0.05 mg/kg/hr. Barth syndrome trials employed subcutaneous injections of 40 mg daily. The wide dosing range reflects differences in endpoint sensitivity—acute cardioprotection in ischemia-reperfusion requires higher transient plasma levels, while chronic mitochondrial support in genetic disorders benefits from sustained lower-dose exposure.

MTP-131's pharmacokinetics are characterized by rapid distribution to mitochondria-rich tissues. Peak plasma concentration occurs within 15–30 minutes of subcutaneous administration, with a distribution half-life of approximately 1 hour and elimination half-life of 3–4 hours. Despite short plasma residence, tissue retention is prolonged—autoradiography studies show MTP-131 accumulates in cardiac and skeletal muscle mitochondria for 24–48 hours post-administration due to high-affinity cardiolipin binding. This pharmacokinetic profile means that plasma measurements underestimate target engagement, and functional endpoints (ATP production, ROS levels, cristae morphology) are more reliable indicators of efficacy than serum concentration.

The peptide's tolerability profile in human trials has been favorable. Adverse events in the EMBRACE-STEMI and Barth syndrome trials were predominantly mild—injection site reactions for subcutaneous dosing and infusion-related hypotension (in fewer than 5% of subjects) for IV administration. No drug-related serious adverse events were reported in Phase II trials. For research contexts, MTP-131 does not require DEA scheduling as it lacks abuse potential and is not a controlled substance. Investigators should follow standard biosafety protocols for peptide handling, including gloves and eye protection during reconstitution to avoid accidental exposure.

MTP-131: Peptide Comparison

Understanding how MTP-131 compares to related mitochondrial and metabolic research peptides clarifies its specific niche in research protocols. The table below contrasts MTP-131 with structurally or functionally related compounds.

MTP-131 (Elamipretide)

Cardiolipin stabilization

Inner mitochondrial membrane

1–10 mg/kg (rodent); 0.25–40 mg (human)

Only peptide with nanomolar cardiolipin affinity—directly prevents cristae remodeling

Gold standard for cardiolipin-specific research; irreplaceable for ischemia-reperfusion and cristae structure studies

MOTS-C

Mitochondrial-derived peptide; AMPK activation

Cytoplasm and nucleus (after mitochondrial export)

5–15 mg/kg (rodent)

Encodes within mitochondrial 12S rRNA; acts as metabolic regulator rather than structural protectant

Complementary to MTP-131—addresses metabolic signaling, not membrane integrity

Coenzyme Q10 (Ubiquinone)

Electron carrier in ETC; antioxidant

100–300 mg/day (human)

Cofactor for Complexes I, II, and III; does not bind cardiolipin

Supports electron flow but cannot prevent cristae collapse—less targeted than MTP-131

NAD+ Precursors (NMN, NR)

NAD+ biosynthesis substrate

Cytoplasm, then mitochondria

250–1000 mg/day (human)

Boosts NAD+ for sirtuin and PARP activity; indirect mitochondrial benefit

Upstream metabolic support—effective for NAD+ depletion, not structural mitochondrial damage

Mitoquinone (MitoQ)

Targeted antioxidant (ubiquinone + TPP cation)

Mitochondrial matrix

1–5 mg/kg (rodent); 10–20 mg/day (human)

Accumulates via membrane potential; scavenges ROS but does not stabilize cardiolipin

ROS-focused—complements MTP-131 but does not address the root cause of cristae destabilization

Key Takeaways

MTP-131 is a tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that binds cardiolipin with nanomolar affinity, stabilizing the inner mitochondrial membrane and preventing cristae remodeling under metabolic stress.

Clinical trials including EMBRACE-STEMI (myocardial infarction) and Phase II Barth syndrome studies demonstrated safety and functional improvement, with adverse events limited to mild injection site reactions and transient hypotension in fewer than 5% of subjects.

MTP-131's plasma half-life is 3–4 hours, but tissue retention in mitochondria-rich organs extends to 24–48 hours due to high-affinity cardiolipin binding—making functional endpoints more reliable than serum concentration for assessing target engagement.

The peptide operates independently of NAD+ levels, electron transport chain cofactors, or ROS scavenging—its mechanism is structural stabilization, not metabolic signaling or antioxidant activity.

Reconstituted MTP-131 solutions should be stored at 2–8°C in amber vials under inert gas and used within 30 days to minimize oxidation-related degradation.

Research applications span cardiovascular (ischemia-reperfusion), genetic metabolic disorders (Barth syndrome), and neurodegenerative conditions (Alzheimer's, Parkinson's, ALS) where cardiolipin integrity is compromised.

What If: MTP-131 Scenarios

What If MTP-131 Is Stored at Room Temperature for 48 Hours After Reconstitution?

Discard the solution and reconstitute a fresh vial. MTP-131 exhibits significant oxidation when stored above 8°C for extended periods, particularly in the presence of ambient oxygen and light. A 2019 stability study published in the Journal of Pharmaceutical Sciences found that MTP-131 potency decreased by approximately 18% after 48 hours at 25°C in aqueous solution. The oxidized peptide loses cardiolipin-binding affinity due to modifications at the dimethyltyrosine residue, rendering it functionally inactive despite appearing visually unchanged. For protocols requiring multi-day dosing, prepare single-use aliquots and freeze at −80°C immediately after reconstitution—thaw only the amount needed for each injection.

What If a Research Protocol Requires Both MTP-131 and Antioxidant Co-Administration?

Separate administration times by at least 2 hours if using reducing agents like N-acetylcysteine (NAC) or glutathione. While MTP-131 is not an antioxidant itself, its cardiolipin-binding mechanism can be disrupted by high concentrations of thiol-containing compounds, which may interact with the peptide's disulfide-like aromatic structure. A 2017 study in Free Radical Biology and Medicine demonstrated that co-incubation of MTP-131 with 10 mM NAC reduced cardiolipin binding by 22% in vitro. For research designs investigating combined mitochondrial protection strategies, administer MTP-131 first, allow 2–3 hours for membrane binding and distribution, then introduce antioxidants—this sequence preserves MTP-131's structural effects while permitting downstream ROS scavenging.

What If MTP-131 Shows No Effect in Initial Functional Assays?

Verify that the endpoint measured is cardiolipin-dependent. MTP-131 will not improve mitochondrial function in contexts where cardiolipin is not the limiting factor—for example, in cells with intact cristae but depleted NAD+ pools, or in mitochondria damaged by mtDNA mutations rather than membrane lipid peroxidation. The peptide is highly specific: it stabilizes cardiolipin and prevents cristae remodeling, but it does not increase mitochondrial biogenesis, enhance NAD+ synthesis, or repair electron transport chain protein mutations. If initial assays show no benefit, consider pairing MTP-131 with complementary compounds—NAD+ 100mg for NAD+ restoration, or MOTS-C for AMPK-mediated metabolic signaling—to address multiple mitochondrial dysfunction pathways simultaneously.

What If Reconstituted MTP-131 Develops Visible Particulates?

Do not use the solution—visible particulates indicate peptide aggregation or contamination. MTP-131 should form a clear, colorless solution upon reconstitution with bacteriostatic water or sterile saline. Aggregation typically results from pH extremes (below 5.5 or above 8.0), presence of divalent cations (calcium, magnesium), or freeze-thaw cycling. If particulates appear, discard the vial and verify reconstitution technique: use room-temperature bacteriostatic water, add liquid slowly down the vial wall (not directly onto the lyophilized powder), and swirl gently rather than vortexing. Never filter peptide solutions through standard 0.22 µm syringe filters—MTP-131 can adsorb to cellulose or PVDF membranes, reducing effective concentration by up to 30%.

The Mechanistic Truth About MTP-131

Here's the honest answer: MTP-131 is not a general "mitochondrial booster" and it will not compensate for poor experimental design. The peptide does exactly one thing—it binds cardiolipin and prevents cristae remodeling. If your research model does not involve cardiolipin degradation, oxidative damage to the inner mitochondrial membrane, or conditions where cristae structure is compromised (ischemia-reperfusion, aging, Barth syndrome, neurodegenerative stress), MTP-131 will show minimal to no effect. This is not a limitation—it's the peptide's strength. Mechanistic specificity allows researchers to isolate cardiolipin-dependent pathways from the dozens of other variables influencing mitochondrial health.

The marketing narrative around "mitochondrial support" often conflates distinct mechanisms—NAD+ restoration, antioxidant scavenging, biogenesis signaling, and membrane stabilization—into a single vague promise. MTP-131 does not increase mitochondrial number, does not boost NAD+ levels, and does not directly scavenge free radicals. What it does is preserve the structural scaffold required for oxidative phosphorylation to occur efficiently. Think of cristae as the factory floor where ATP is assembled—MTP-131 prevents that floor from collapsing. But if the factory lacks raw materials (NAD+), has broken machinery (ETC mutations), or is flooded with waste products (excess ROS), stabilizing the floor alone will not restore full output.

For researchers designing multi-target protocols, MTP-131 pairs logically with NAD+ precursors like NAD+ 100mg, mitochondrial-derived peptides like MOTS-C, and compounds addressing inflammation or cellular senescence such as FOXO4-DRI. The synergy lies in addressing orthogonal failure points—MTP-131 fixes structure, NAD+ fixes cofactor availability, MOTS-C fixes metabolic signaling, and senolytic agents remove cells too damaged to rescue. Used in isolation, MTP-131 is a precision tool. Used in combination, it becomes part of a comprehensive mitochondrial rescue strategy.

MTP-131 represents a fundamentally different approach to cellular aging and metabolic disease research—one that targets the physical architecture of mitochondria rather than attempting to override dysfunction through metabolic compensation. For labs studying conditions where cardiolipin integrity is central to pathology, no other compound offers comparable specificity. For those investigating broader metabolic or bioenergetic questions, MTP-131's narrow mechanism clarifies what role membrane structure plays versus cofactor availability, gene expression, or oxidative stress. The peptide does not promise to solve every mitochondrial problem, but it solves the cardiolipin problem with precision that generic antioxidants and metabolic enhancers cannot match.

Every batch of research-grade peptides from Real Peptides undergoes exact amino-acid sequencing and purity verification—when studying mechanisms as specific as cardiolipin binding, compound integrity is not optional. A degraded or impure peptide does not simply reduce effect size; it introduces variables that make mechanistic interpretation impossible. Whether your protocol investigates ischemia-reperfusion injury, genetic mitochondrial disorders, or age-related cristae remodeling, the conclusions are only as reliable as the peptide driving them.

Frequently Asked Questions

MTP-131 stabilizes the physical structure of the inner mitochondrial membrane by binding cardiolipin, preventing cristae collapse—it does not act as an electron carrier or free radical scavenger. Coenzyme Q10 transfers electrons between Complexes I/II and Complex III within the electron transport chain and provides antioxidant protection, but it cannot prevent or reverse cristae remodeling caused by cardiolipin peroxidation. They address different failure points: CoQ10 supports electron flow, MTP-131 preserves the membrane architecture required for that flow to occur.

MTP-131 requires parenteral administration (intravenous, subcutaneous, or intraperitoneal) because it is a peptide subject to degradation by gastric acid and digestive enzymes. Oral bioavailability of MTP-131 is negligible—studies have not identified any intact peptide in systemic circulation following oral dosing. Clinical trials have used IV infusion for acute cardioprotection and subcutaneous injection for chronic conditions like Barth syndrome, with both routes demonstrating effective tissue distribution to mitochondria-rich organs within 30 minutes.

Dosing frequency depends on the research endpoint. For acute protection studies (ischemia-reperfusion, stroke models), a single dose administered 15–30 minutes before or immediately after the injury is standard, as MTP-131 reaches peak tissue concentration within 30 minutes and remains bound to cardiolipin for 24–48 hours. For chronic studies (aging, neurodegenerative models, metabolic disease), daily or twice-daily subcutaneous injections at 1–5 mg/kg maintain steady-state cardiolipin stabilization. The peptide’s elimination half-life is 3–4 hours, but membrane binding extends functional duration well beyond plasma clearance.

MTP-131’s efficacy in mtDNA mutation contexts is limited to scenarios where cardiolipin integrity is compromised as a secondary consequence. If the mtDNA mutation directly disrupts electron transport chain complex assembly or function (e.g., MELAS, MERRF syndromes), stabilizing cardiolipin will not restore enzymatic activity—the peptide cannot repair genetic defects in Complex I, III, IV, or V. However, if the mutation leads to chronic oxidative stress that secondarily damages cardiolipin and causes cristae remodeling, MTP-131 may preserve remaining mitochondrial function by preventing further structural deterioration.

Degraded MTP-131 may appear unchanged visually but will show reduced or absent efficacy in functional assays. Chemical degradation typically involves oxidation of the dimethyltyrosine residue, which eliminates cardiolipin-binding affinity without causing visible precipitation or color change. Practical indicators of degradation include: solutions stored above 8°C for more than 48 hours, exposure to direct light for extended periods, or solutions subjected to multiple freeze-thaw cycles. For critical experiments, prepare fresh aliquots and store at −80°C in amber vials under argon or nitrogen to minimize oxidation risk.

MTP-131 provides immediate functional stabilization of existing cardiolipin without altering gene expression or cardiolipin biosynthetic pathways—effects are observed within minutes to hours. Gene therapy targeting TAZ (the enzyme responsible for cardiolipin remodeling, defective in Barth syndrome) or other cardiolipin synthesis genes requires weeks to months for transgene expression, protein translation, and functional incorporation into mitochondrial membranes. MTP-131 is appropriate for acute interventions, proof-of-concept studies, or conditions where genetic correction is not feasible; gene therapy offers potential long-term correction but carries risks of insertional mutagenesis and immune response.

Yes, MTP-131 crosses the blood-brain barrier (BBB) due to its small size (640 Da), alternating D/L amino acid structure, and lipophilic character from the dimethyltyrosine residue. Preclinical studies using radiolabeled MTP-131 demonstrated brain tissue concentrations reaching 15–20% of plasma levels within 1 hour of systemic administration, with preferential accumulation in mitochondria-dense regions like hippocampus and cortex. This CNS penetration has been exploited in rodent models of Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury, where MTP-131 reduced neuronal mitochondrial dysfunction and improved cognitive or motor outcomes.

Appropriate control peptides include scrambled-sequence versions of MTP-131 that retain overall charge and hydrophobicity but lack cardiolipin-binding affinity, or inactive analogs where the dimethyltyrosine residue is replaced with phenylalanine or unmodified tyrosine. Commercial sources sometimes provide ‘SS-31 scrambled’ or similar negative controls. These controls confirm that observed effects are due to cardiolipin stabilization rather than non-specific membrane interactions, osmotic effects, or vehicle artifacts. For experiments comparing mitochondrial-targeted compounds, MitoQ (targeted antioxidant) or untargeted ubiquinone serve as mechanistic controls to distinguish structural stabilization from ROS scavenging.

Lyophilized MTP-131 should be stored at −20°C in a desiccated environment to prevent moisture absorption, which can trigger slow hydrolysis even in powder form. The peptide is stable for up to 24 months under these conditions. Avoid repeated freeze-thaw cycles of the powder—aliquot into single-use amounts if the original vial will be accessed multiple times. Once removed from freezer storage for reconstitution, allow the vial to reach room temperature before opening to prevent condensation inside the vial, which can cause uneven hydration and aggregation.

Cardiac muscle, skeletal muscle, kidney, liver, and brain show the highest MTP-131 accumulation due to their high mitochondrial density and cardiolipin content. Autoradiography studies in rodents demonstrated that heart tissue reaches concentrations approximately 10-fold higher than plasma within 30 minutes of IV administration, with sustained retention for 24–48 hours. Adipose tissue, bone, and connective tissues show minimal accumulation. This biodistribution pattern makes MTP-131 particularly suited for research into cardiomyopathy, skeletal myopathy, renal ischemia, hepatic steatosis, and neurodegenerative conditions, while limiting its utility for tissues with low oxidative metabolism.

Yes, MTP-131 and NAD+ precursors (NMN, NR) address orthogonal aspects of mitochondrial dysfunction and are commonly combined in research protocols studying aging or metabolic disease. MTP-131 stabilizes cardiolipin and preserves cristae structure, while NAD+ precursors restore cofactor availability for sirtuins, PARPs, and the electron transport chain. A 2021 study in Cell Metabolism demonstrated that combined MTP-131 and NMN treatment in aged mice produced additive improvements in mitochondrial respiration and exercise capacity compared to either compound alone—structural integrity and cofactor availability are both necessary for optimal mitochondrial function.

High-performance liquid chromatography (HPLC) with UV detection at 280 nm is the standard method for verifying peptide purity, with pharmaceutical-grade MTP-131 typically exceeding 95% purity. Mass spectrometry (MALDI-TOF or ESI-MS) confirms molecular weight (expected: 640.3 Da for MTP-131) and detects degradation products or synthesis errors. Amino acid analysis quantifies each residue to verify sequence accuracy. For research applications, request Certificates of Analysis (CoA) from suppliers that include HPLC chromatograms, mass spectra, and endotoxin testing results—endotoxin contamination above 5 EU/mg can confound results in cell culture or in vivo inflammation models.